The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $12.00 expecting ABCL to rise to within 12 months (a possible 141.21% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Benchmark, and AbCellera Biologics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a maintained with a price target of $20.00 to $12.00. The current price AbCellera Biologics (ABCL) is trading at is $4.97, which is out of the analyst’s predicted range.

The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $12.00 expecting ABCL to rise to within 12 months (a possible 141.21% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Benchmark, and AbCellera Biologics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a maintained with a price target of $20.00 to $12.00. The current price AbCellera Biologics (ABCL) is trading at is $4.97, which is out of the analyst’s predicted range.

The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $12.00 expecting ABCL to rise to within 12 months (a possible 141.21% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Benchmark, and AbCellera Biologics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a maintained with a price target of $20.00 to $12.00. The current price AbCellera Biologics (ABCL) is trading at is $4.97, which is out of the analyst’s predicted range.

The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $12.00 expecting ABCL to rise to within 12 months (a possible 141.21% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Benchmark, and AbCellera Biologics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a maintained with a price target of $20.00 to $12.00. The current price AbCellera Biologics (ABCL) is trading at is $4.97, which is out of the analyst’s predicted range.

The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $12.00 expecting ABCL to rise to within 12 months (a possible 141.21% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Benchmark, and AbCellera Biologics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a maintained with a price target of $20.00 to $12.00. The current price AbCellera Biologics (ABCL) is trading at is $4.97, which is out of the analyst’s predicted range.

The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $12.00 expecting ABCL to rise to within 12 months (a possible 141.21% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Benchmark, and AbCellera Biologics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a maintained with a price target of $20.00 to $12.00. The current price AbCellera Biologics (ABCL) is trading at is $4.97, which is out of the analyst’s predicted range.

The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $12.00 expecting ABCL to rise to within 12 months (a possible 141.21% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Benchmark, and AbCellera Biologics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a maintained with a price target of $20.00 to $12.00. The current price AbCellera Biologics (ABCL) is trading at is $4.97, which is out of the analyst’s predicted range.

The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Benchmark on August 31, 2023. The analyst firm set a price target for $12.00 expecting ABCL to rise to within 12 months (a possible 141.21% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Benchmark, and AbCellera Biologics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on August 31, 2023 so you should expect the next rating to be made available sometime around August 31, 2024.

While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a maintained with a price target of $20.00 to $12.00. The current price AbCellera Biologics (ABCL) is trading at is $4.97, which is out of the analyst’s predicted range.